ClinicalTrials.gg
CompletedNCT02737332STAARUpdated Nov 22, 2021Results posted

A Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer

A Phase 2 interventional study of Zytiga® (Abiraterone Acetate) and SoluMatrix™ (Abiraterone Acetate) in Prostate Cancer, sponsored by Sun Pharmaceutical Industries Limited. Completed at 17 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-11-22.

Sponsored by Sun Pharmaceutical Industries Limited · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
53
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies testing Abiraterone Acetate in Prostatic Neoplasms — 12 open to participants now, 29 under way, 4 of them phase 3. Abiraterone Acetate · Prostatic Neoplasms.

Enrollment
52nd of 98
53 · median 56
Started
2016
with 6 others
Phase 2
59 of 98
9 open now
Registered
49th of 98
by date
Lead sponsor
3 of 98
Sun Pharmaceutical Industries Limited

Among the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, this one is the 52nd largest by enrollment, is one of 7 that started in 2016, is one of 59 in phase 2, and was the 49th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

12 of the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About Abiraterone Acetate

Abiraterone Acetate: first FDA approval 2011 (ZYTIGA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the serum testosterone levels in patients with Metastatic Castration-Resistant Prostate Cancer on SoluMatrix™ Abiraterone Acetate as Compared to Abiraterone Acetate

Read the detailed description

This was a 12-week, open-label study of abiraterone acetate in at least 50 patients with metastatic castration-resistant prostate cancer.

03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written obtained prior to any study-related procedure being performed
  2. Male subjects at least 18 years of age or older at time of consent
  3. confirmed adenocarcinoma of the prostate
  4. Ongoing therapy with a GnRH agonist or antagonist AND serum testosterone level \<50 ng/dL at screening
  5. disease documented by computed tomography (CT)/ magnetic resonance imaging (MRI) or bone scan. Imaging obtained within 42 days prior to the start of study medication will be accepted.
  6. Meeting disease progression according to the recommendations of the prostate cancer working group 2 by one of the following criteria:

    • Two rises of PSA (taken a minimum of 1 week apart) from a baseline measurement of at least 2 ng/mL,
    • Imaging progression (CT/MRI) by criteria
    • Nuclear scan progression by new lesion.
  7. Discontinuation of flutamide or nilutamide, and other anti-androgens at least 4 weeks prior to the start of study medication; discontinuation of bicalutamide at least 6 weeks prior to start of study medication.
  8. Discontinuation of Radiotherapy > 4 weeks prior to start of study medication.
  9. performance status of 0-1 at screening
  10. Screening blood counts of the following:

    • > 1500/µL
    • > 100,000/µL
    • > 9 g/dL
  11. Screening chemistry values of the following:

    • and AST \< 2.5 x
    • Total \< 1.5 x ULN
    • Creatinine\< 1.5 x ULN
    • Albumin > 3.0 g/dL
  12. Potassium > 3.5 mmol/L
  13. of at least 6 months at screening
  14. Subject is willing and able to comply with all protocol requirements assessments
  15. Agrees to protocol-defined use of effective .

Exclusion criteria

Exclusion Criteria:

  1. History of impaired pituitary or adrenal gland function
  2. Prior therapy with abiraterone acetate, orteronel, ketoconazole or any other CYP17 inhibitor
  3. Prior therapy with enzalutamide
  4. Prior use of experimental androgen receptor antagonist
  5. Previous exposure to Ra-223:Xofigo
  6. Previous chemotherapy
  7. Initiation of bisphosphonate or denosumab therapy within 30 days prior to the start of study medication. Patients who are on a stable dose of these medications for at least 30 days at the time of starting study drug are eligible.
  8. Therapy with estrogen within 30 days prior to the start of study medication
  9. Use of systemic equivalent to > 10 mg of prednisone daily; patients who have discontinued or have reduced dose to \< 10 mg prednisone within 14 days prior to the start of study medication will be eligible
  10. Prior use of any herbal products that may decrease PSA levels (eg., saw palmetto) within 30 days of start of study medication
  11. Known to the brain or CNS involvement
  12. History of other within the previous 2 years
  13. Major surgery within 30 days prior to the start of study medication
  14. Blood transfusion within 30 days of screening
  15. Serious, persistent infection within 14 days of the start of study medication
  16. Persistent pain that requires the use of a narcotic analgesic
  17. Known gastrointestinal disease or condition that may impair absorption
  18. Treatment with any drug within 4 weeks prior to Day -1 of the study.
  19. Known history of (HIV) or seropositive test for virus or virus
  20. Have poorly controlled diabetes.
  21. Uncontrolled hypertension
  22. History of (NYHA) class III or IV heart failure
  23. Serious concurrent illness, including psychiatric illness, that would interfere with study participation
  24. Inability to swallow tablets whole
  25. Known to any in study medications
  26. Moderate to severe hepatic impairment ( Classes B and C)
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
53 participants (actual)

Study arms

  • Active comparator
    Zytiga® (Abiraterone Acetate)

    1,000 MG (4 x 250 mg qd)

    Drug: Zytiga® (Abiraterone Acetate)

  • Experimental
    SoluMatrix™ (Abiraterone Acetate)

    500 mg (4 x 125 mg qd)

    Drug: SoluMatrix™ (Abiraterone Acetate)

Interventions

  • Zytiga® 1,000 mg (4 x 250 mg qd) tablets plus one 5 mg prednisone tablet to be taken bid, spaced approximately 12 hours apart

    Also known as: Zytiga®

  • SoluMatrix™ 500 mg (4 x 125 mg qd) tablets plus one 4 mg methylprednisolone tablet bid, spaced approximately 12 hours apart

    Also known as: SoluMatrix™

06

What researchers measure

Primary outcomes

  1. Testosterone Levels

    Blood Sample tested for Serum Testosterone Levels

    Time frame: Average of Day 9 and 10

Secondary outcomes

  1. PSA Levels

    All patients randomized to one of the two treatment groups, round about level of PSA. These were assessed only at the said Outcome Measure Time Frame. No additional time points to the said endpoint

    Time frame: Day 28, Day 56, and Day 84

  2. Percent of Subjects With PSA-50 Response

    Proportion of patients with complete suppression of PSA-50 were reported by treatment and compared for between-group differences. These were assessed only at the said Outcome Measure Time Frame. No additional time points to the said endpoint.

    Time frame: Day 28, Day 56, and Day 84

  3. Serum Testosterone Levels

    These were assessed only at the said Outcome Measure Time Frame. No additional time points to the said endpoint.

    Time frame: Day 28, Day 56, and Day 84

  4. Steady State Trough Concentration of Arbiraterone

    These were assessed only at the said Outcome Measure Time Frame. No additional time points to the said endpoint.

    Time frame: Day 09, Day 28, Day 56, and Day 84

  5. AUC (0-inf)

    Steady state systemic exposure parameters

    Time frame: 60 to 30 minutes prior to dosing and over 24 Hours post-dose

  6. AUC (0-24 hr)

    Blood samples for pre-dose PK profiling were to be collected approximately 45 minutes before dosing, i.e., within 60 to 30 minutes prior to dosing. Post-dose blood samples were to be collected throughout the day at the times (15 mins, 30 mins, 1 hr, 1.5 hr, 2.0 hr 3 hr, 4 hr, 6 hr, 8 hr, 9 hr, 24 hr).

    Time frame: 60 to 30 minutes prior to dosing and over 24 Hours post-dose

  7. AUC (0-t)

    Blood samples for pre-dose PK profiling were to be collected approximately 45 minutes before dosing, i.e., within 60 to 30 minutes prior to dosing. Post-dose blood samples were to be collected throughout the day at the times (15 mins, 30 mins, 1 hr, 1.5 hr, 2.0 hr 3 hr, 4 hr, 6 hr, 8 hr, 9 hr, 24 hr).

    Time frame: 60 to 30 minutes prior to dosing and over 24 Hours post-dose

  8. Cmax

    Blood samples for pre-dose PK profiling were to be collected approximately 45 minutes before dosing, i.e., within 60 to 30 minutes prior to dosing. Post-dose blood samples were to be collected throughout the day at the times (15 mins, 30 mins, 1 hr, 1.5 hr, 2.0 hr 3 hr, 4 hr, 6 hr, 8 hr, 9 hr, 24 hr).

    Time frame: 60 to 30 minutes prior to dosing and over 24 Hours post-dose

07

Results

Posted Aug 12, 2020

Participant flow

Participant flow — Overall Study
MilestoneZytiga® (Abiraterone Acetate)SoluMatrix™ (Abiraterone Acetate)
Started2924
Completed2823
Not completed11

Outcome measures

PrimaryTestosterone Levels

Blood Sample tested for Serum Testosterone Levels

Time frame:
Average of Day 9 and 10
Reported as:
Mean · ng/dL
Testosterone Levels
ng/dLZytiga® (Abiraterone Acetate)SoluMatrix™ (Abiraterone Acetate)
Testosterone Levels1.02 ± 0.031.05 ± 0.04
Statistical analysis
  • Zytiga® (Abiraterone Acetate) vs SoluMatrix™ (Abiraterone Acetate) · ANOVA · p = 0.4879 (One-way ANOVA model with treatment as the independent variable, and the least-square means and standard error of Testosterone levels under each treatment and the between-treatment difference in LS means was reported.) · Geometric mean ratio of treatments: 1.019 · 90% CI 0.964 to 1.077Geometric mean ratio of experimental and reference product was determined by exponentiating least-squares means of log-transformed value.
SecondaryPSA Levels

All patients randomized to one of the two treatment groups, round about level of PSA. These were assessed only at the said Outcome Measure Time Frame. No additional time points to the said endpoint

Time frame:
Day 28, Day 56, and Day 84
Reported as:
Least squares mean · ng/mL
PSA Levels
ng/mLZytiga® (Abiraterone Acetate)SoluMatrix™ (Abiraterone Acetate)
Day 2837.5 ± 11.3322.37 ± 12.02
Day 5640.84 ± 12.5825.29 ± 13.68
Day 8433.88 ± 13.4326.46 ± 15.41
Statistical analysis
  • Zytiga® (Abiraterone Acetate) vs SoluMatrix™ (Abiraterone Acetate) · ANOVA · p = 0.3642 (One-way ANOVA model with treatment as the independent variable, and the least-square means and standard error of Testosterone levels under each treatment and the between-treatment difference in LS means was reported.) · Geometric mean ratio: 0.994 · 90% CI 0.0451 to 2.192Geometric mean ratio of experimental and reference product was determined by exponentiating least-squares means of log-transformed value.
  • Zytiga® (Abiraterone Acetate) vs SoluMatrix™ (Abiraterone Acetate) · ANOVA · p = 0.4069 (One-way ANOVA model with treatment as the independent variable, and the least-square means and standard error of Testosterone levels under each treatment and the between-treatment difference in LS means was reported.) · Geometric mean ratio: 0.810 · 90% CI 0.338 to 1.939Geometric mean ratio of experimental and reference product was determined by exponentiating least-squares means of log-transformed value.
  • Zytiga® (Abiraterone Acetate) vs SoluMatrix™ (Abiraterone Acetate) · ANOVA · p = 0.7186 (The bioequivalence between the two products was concluded if the 90% CIs (based on log transformed data and anti-logged) for the ratio of the geometric means lie completely within the range 80%-125%.) · Geometric mean ratio: 1.039 · 90% CI 0.412 to 2.617Geometric mean ratio of experimental and reference product was determined by exponentiating least-squares means of log-transformed value.
SecondaryPercent of Subjects With PSA-50 Response

Proportion of patients with complete suppression of PSA-50 were reported by treatment and compared for between-group differences. These were assessed only at the said Outcome Measure Time Frame. No additional time points to the said endpoint.

Time frame:
Day 28, Day 56, and Day 84
Reported as:
Number · percentage of Participants
Percent of Subjects With PSA-50 Response
percentage of ParticipantsZytiga® (Abiraterone Acetate)SoluMatrix™ (Abiraterone Acetate)
Day 2870.466.7
Day 5665.463.6
Day 8472.068.4
Statistical analysis
  • Zytiga® (Abiraterone Acetate) vs SoluMatrix™ (Abiraterone Acetate) · Fisher Exact · p = 1.0000
SecondarySerum Testosterone Levels

These were assessed only at the said Outcome Measure Time Frame. No additional time points to the said endpoint.

Time frame:
Day 28, Day 56, and Day 84
Reported as:
Mean · ng/dL
Serum Testosterone Levels
ng/dLZytiga® (Abiraterone Acetate)SoluMatrix™ (Abiraterone Acetate)
Day 281.01 ± 0.011.01 ± 0.01
Day 561.01 ± 1.032.56 ± 1.07
Day 841 ± 01 ± 0
Statistical analysis
  • Zytiga® (Abiraterone Acetate) vs SoluMatrix™ (Abiraterone Acetate) · ANOVA · p = 0.9211 (One-way ANOVA model with treatment as the independent variable, and the least-square means and standard error of Testosterone levels under each treatment and the between-treatment difference in LS means was reported.) · Geometric mean ratio: 0.999 · 90% CI 0.980 to 1.018Geometric mean ratio of experimental and reference product was determined by exponentiating least-squares means of log-transformed value.
  • Zytiga® (Abiraterone Acetate) vs SoluMatrix™ (Abiraterone Acetate) · ANOVA · p = 0.3037 (One-way ANOVA model with treatment as the independent variable, and the least-square means and standard error of Testosterone levels under each treatment and the between-treatment difference in LS means was reported.) · Geometric mean ratio: 1.168 · 90% CI 0.900 to 1.515Geometric mean ratio of experimental and reference product was determined by exponentiating least-squares means of log-transformed value.
  • Zytiga® (Abiraterone Acetate) vs SoluMatrix™ (Abiraterone Acetate) · ANOVA · Geometric mean ratio: 1.000 · 90% CI 1.000 to 1.000Geometric mean ratio of experimental and reference product was determined by exponentiating least-squares means of log-transformed value.
SecondarySteady State Trough Concentration of Arbiraterone

These were assessed only at the said Outcome Measure Time Frame. No additional time points to the said endpoint.

Time frame:
Day 09, Day 28, Day 56, and Day 84
Reported as:
Least squares mean · ng/dL
Steady State Trough Concentration of Arbiraterone
ng/dLZytiga® (Abiraterone Acetate)SoluMatrix™ (Abiraterone Acetate)
Day 0920.938 ± 7.04427.259 ± 7.772
Day 2856.721 ± 23.10418.662 ± 24.18
Day 5629.978 ± 8.11718.707 ± 9.175
Day 8418.263 ± 3.08713.819 ± 3.381
Statistical analysis
  • Zytiga® (Abiraterone Acetate) vs SoluMatrix™ (Abiraterone Acetate) · ANOVA · p = 0.5495
  • Zytiga® (Abiraterone Acetate) vs SoluMatrix™ (Abiraterone Acetate) · ANOVA · p = 0.2616
  • Zytiga® (Abiraterone Acetate) vs SoluMatrix™ (Abiraterone Acetate) · ANOVA · p = 0.3632
  • Zytiga® (Abiraterone Acetate) vs SoluMatrix™ (Abiraterone Acetate) · ANOVA · p = 0.3393
SecondaryAUC (0-inf)

Steady state systemic exposure parameters

Time frame:
60 to 30 minutes prior to dosing and over 24 Hours post-dose
Reported as:
Least squares mean · ng*hr/mL
AUC (0-inf)
ng*hr/mLZytiga® (Abiraterone Acetate)SoluMatrix™ (Abiraterone Acetate)
AUC (0-inf)1020.218 ± 154.549326.458 ± 218.565
SecondaryAUC (0-24 hr)

Blood samples for pre-dose PK profiling were to be collected approximately 45 minutes before dosing, i.e., within 60 to 30 minutes prior to dosing. Post-dose blood samples were to be collected throughout the day at the times (15 mins, 30 mins, 1 hr, 1.5 hr, 2.0 hr 3 hr, 4 hr, 6 hr, 8 hr, 9 hr, 24 hr).

Time frame:
60 to 30 minutes prior to dosing and over 24 Hours post-dose
Reported as:
Least squares mean · ng*hr/mL
AUC (0-24 hr)
ng*hr/mLZytiga® (Abiraterone Acetate)SoluMatrix™ (Abiraterone Acetate)
AUC (0-24 hr)870.859 ± 221.709626.066 ± 280.443
SecondaryAUC (0-t)

Blood samples for pre-dose PK profiling were to be collected approximately 45 minutes before dosing, i.e., within 60 to 30 minutes prior to dosing. Post-dose blood samples were to be collected throughout the day at the times (15 mins, 30 mins, 1 hr, 1.5 hr, 2.0 hr 3 hr, 4 hr, 6 hr, 8 hr, 9 hr, 24 hr).

Time frame:
60 to 30 minutes prior to dosing and over 24 Hours post-dose
Reported as:
Least squares mean · ng*hr/mL
AUC (0-t)
ng*hr/mLZytiga® (Abiraterone Acetate)SoluMatrix™ (Abiraterone Acetate)
AUC (0-t)870.859 ± 221.709626.066 ± 280.443
SecondaryCmax

Blood samples for pre-dose PK profiling were to be collected approximately 45 minutes before dosing, i.e., within 60 to 30 minutes prior to dosing. Post-dose blood samples were to be collected throughout the day at the times (15 mins, 30 mins, 1 hr, 1.5 hr, 2.0 hr 3 hr, 4 hr, 6 hr, 8 hr, 9 hr, 24 hr).

Time frame:
60 to 30 minutes prior to dosing and over 24 Hours post-dose
Reported as:
Least squares mean · ng/mL
Cmax
ng/mLZytiga® (Abiraterone Acetate)SoluMatrix™ (Abiraterone Acetate)
Cmax268.261 ± 69.967111.316 ± 88.503
Statistical analysis
  • Zytiga® (Abiraterone Acetate) vs SoluMatrix™ (Abiraterone Acetate) · ANOVA · p = 0.1917

Adverse events

Collected over AEs were collected from the time of signing of the ICF until study completion (84 Days). The AEs collected in the source documents for screening failures did not need to be entered into eCRF, however once a potential patient was randomized, all AEs were to be entered into the eCRF.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Zytiga® (Abiraterone Acetate)2/29 (6.9%)2/29 (6.9%)22/29 (75.9%)
SoluMatrix™ (Abiraterone Acetate)0/24 (0%)5/24 (20.8%)16/24 (66.7%)
Most frequent serious events
Most frequent serious events
EventZytiga® (Abiraterone Acetate)SoluMatrix™ (Abiraterone Acetate)
Corornary artery diseaseCardiac disorders0/291/24
SepsisInfections and infestations0/291/24
PyelonephritisInfections and infestations0/291/24
VertigoInfections and infestations0/291/24
Worsening of left hydroureteronephrosisRenal and urinary disorders0/291/24
Progression of prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/290/24
Myocardial infarctionCardiac disorders1/290/24
Most frequent other events
Showing 10 of 17
Most frequent other events
EventZytiga® (Abiraterone Acetate)SoluMatrix™ (Abiraterone Acetate)
Urinary tract infectionsInfections and infestations3/294/24
Back painMusculoskeletal and connective tissue disorders4/291/24
Muscle spasmsMusculoskeletal and connective tissue disorders4/291/24
DizzinessNervous system disorders4/290/24
NauseaGastrointestinal disorders3/290/24
Abdominal painGastrointestinal disorders0/292/24
Oedema peripheralGeneral disorders0/292/24
VomitingGastrointestinal disorders2/290/24
AstheniaGeneral disorders2/290/24
Blood creatiineincreasedInvestigations2/290/24

Baseline characteristics

Age, Continuous
Age, Continuous(years)Zytiga® (Abiraterone Acetate)SoluMatrix™ (Abiraterone Acetate)Total
Mean73.5 ± 9.477 ± 8.975.1 ± 9.3
Sex: Female, Male
Sex: Female, Male(Participants)Zytiga® (Abiraterone Acetate)SoluMatrix™ (Abiraterone Acetate)Total
Female000
Male292453
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Zytiga® (Abiraterone Acetate)SoluMatrix™ (Abiraterone Acetate)Total
Hispanic or Latino246
Not Hispanic or Latino272047
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Zytiga® (Abiraterone Acetate)SoluMatrix™ (Abiraterone Acetate)Total
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American8311
White202040
More than one race000
Unknown or Not Reported101
Region of Enrollment
Region of Enrollment(participants)Zytiga® (Abiraterone Acetate)SoluMatrix™ (Abiraterone Acetate)Total
United States292453
08

Study locations

17 sites
  • Alliance Research
    Laguna Hills, California 92653, United States
  • Tower Urology
    Los Angeles, California 90048, United States
  • San Bernardino Urological
    San Bernardino, California 92404, United States
  • Skyline Urology
    Torrance, California 90505, United States
  • Innovative Clinical Research Institute
    Whittier, California 90603, United States
  • Urology Associates, P.C.
    Englewood, Colorado 80113, United States
  • Manatee Medical Research
    Bradenton, Florida 34205, United States
  • North Idaho Urology
    Coeur d'Alene, Idaho 83814, United States
  • The Iowa Clinic
    West Des Moines, Iowa 50266, United States
  • Wichita Urology Group
    Wichita, Kansas 67226, United States
  • Chesapeake Urology Research Associates
    Towson, Maryland 21204, United States
  • Lincoln Urology, PC
    Lincoln, Nebraska 68516, United States
  • Urology Cancer Center
    Omaha, Nebraska 68130, United States
  • Brooklyn Urology Research Group
    Brooklyn, New York 11215, United States
  • Associated Urologist of North Carolina
    Raleigh, North Carolina 27612, United States
  • Urology Clinics of North Texas
    Dallas, Texas 75231, United States
  • Urology of Virginia
    Virginia Beach, Virginia 23462, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2016 to primary completion in Feb 2017, 11 months.

Results were first posted in Aug 2020, 3 years 5 months after primary completion.

Of 114 industry-sponsored phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 45. This study's 11 months is below that.

Counting every sponsor, half of 724 studies reached it within 53 months; a quarter within 34 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2016
First posted
Apr 13, 2016
StartActual
Mar 21, 2016
Primary completionActual
Feb 27, 2017
CompletionActual
Feb 27, 2017
Results first posted
Aug 12, 2020
Last update
Nov 22, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02737332
Responsible party
Sponsor
First posted
Apr 13, 2016
Start date
Mar 21, 2016
Primary completion
Feb 27, 2017
Completion
Feb 27, 2017
Results posted
Aug 12, 2020
Last update
Nov 22, 2021

Study contacts

Paul Nemeth, PhD
study director

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abiraterone Acetate

Start the discussion